Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

About this update from Biocytogen Pharmaceuticals (beijing) Co. Ltd. Class A

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":240,"url":"https://media.zenfs.com/en/business-wire.com/3f303581bfd17ca066c62585a859fcda"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D_BfVx2nY7EHeegBIVaPfg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3f303581bfd17ca066c62585a859fcda","width":480,"height":240}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161.","length":212,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK.","length":117,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement.","length":117,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":446,"olType":false},{"type":"text","content":"BEIJING, February 28, 2026--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. ("IDEAYA"; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million milestone payment to Biocytogen.","length":639,"tagName":"p"},{"type":"text","content":"According to IDEAYA, the Phase 1 study is designed to characterize IDE034’s safety profile, tolerability, and PK as a monotherapy, and IDEAYA also intends to evaluate combination regimens with DNA damage response (DDR) -targeting agents such as its oral PARG inhibitor IDE161 as the program advances.","length":300,"tagName":"p"},{"type":"text","content":"IDE034 is a potential first-in-class bisp...

More updates from Biocytogen Pharmaceuticals (beijing) Co. Ltd. Class A